U.S. markets open in 5 hours 10 minutes

DermTech, Inc. (DMTK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6300-0.0200 (-1.21%)
At close: 04:00PM EDT
1.6200 -0.01 (-0.61%)
After hours: 05:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close1.6500
Bid0.0000 x 1200
Ask0.0000 x 800
Day's Range1.6000 - 1.6500
52 Week Range1.5500 - 6.4400
Avg. Volume272,746
Market Cap54.897M
Beta (5Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)-3.8000
Earnings DateNov 01, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DMTK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • DermTech, Inc.
    CELH: Lowering target price to $145.00CELSIUS HOLDINGS INC has an Investment Rating of SELL; a target price of $145.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Business Wire

    DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

    SAN DIEGO, September 21, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard. The award was granted pursuant to the terms of Mr. Aguillard’s employment letter and as a material inducement to his joining the Company as chief commercial officer.

  • Business Wire

    DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)

    SAN DIEGO, September 19, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark). The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, Wes


    Insider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 Shares

    On September 11, 2023, Kevin Sun, the Chief Financial Officer (CFO) of DermTech Inc (NASDAQ:DMTK), sold 9,616 shares of the company.